Polymorphic Post-Transplant Lymphoproliferative Disorder
2 clinical trials · Condition
◉ Watch Polymorphic Post-Transplant Lymphoproliferative Disorder
| Record | Firm | Date |
|---|---|---|
| Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder (NCT05786040) | Timothy Voorhees | 2023-03-23 |
| Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder (NCT02900976) | Children's Oncology Group | 2017-03-22 |
Track Polymorphic Post-Transplant Lymphoproliferative Disorder automatically
Every clearance here is in the API, with alerts when new ones post.